Scalper1 News
Big Swiss pharma Roche (RHHBY) halted development of its Alzheimer’s disease drug and reported mediocre results from a clinical trial of breast-cancer drug Kadcyla Friday, sending the stock down more than 6% in early trading on the stock market today, though by late morning it was down just a fraction. Roche said it was stopping its phase-three trial of gantenerumab in patients with early-stage Alzheimer’s disease after a futility analysis Scalper1 News
Scalper1 News